The ubiquitin-proteasome pathway is one of important pathways during selective protein degradation,which participates in many intracellular physiological and biochemical processes.Bortezomib,a kind of proteasome inhibitor,can inhibit cell growth and proliferation,induce cell apoptosis and overcome drug resistance in chemotherapy.The mechanisms of bortezomib on the therapy of multiple myeloma are reviewed in this paper.